An observational study in Geriatric Assessment, Geriatric Patients and Patients With Cancer, sponsored by Sichuan Cancer Hospital and Research Institute. Enrolling by invitation at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-05-15.
Sponsored by Sichuan Cancer Hospital and Research Institute · Observational
This study is an observational research.
Sichuan Cancer Hospital and Research Institute is the lead sponsor of 62 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Among all participants, 316 were used to develop the screening tool, 10 for the pre-testing, and 132 for the reliability and validity testing of the screening scale. After the scale was completed, the remaining 220 patients were used for the external validation of the tool. Finally, all patients evaluated using the screening tool were grouped according to different screening results, and the treatment effects and risks among the groups were compared.
Exclusion Criteria:
Elderly cancer patients were assessed with the screening tool and G8. If the patient's screening result is positive (frailty risk population), continue with the CGA.
Other: Screening of comprehensive geriatic assessment. · Other: the G8 assessment · Other: Comprehensive Geriatric Assessment (CGA)
The participants are screened before anti-tumor therapy with a comprehensive assessment screening tool developed for elderly cancer patients, which is more suitable for individualized decision-making in anti-tumor treatment.
The G8 is a rapid geriatric screening test that takes only a few minutes to complete. It is used as a calibration standard to validate the novel screening tool in this study.
The participants screened as a high frailty risk will undergo CGA to determine the most appropriate treatment plan.
Sensitivity
(Truly frail elderly patients assessed by the novel screening tool and G8) / (Truly frail risk patients + elderly patients with negative results from novel screening tool but actually at risk of frailty after G8 assessment
Time frame: Baseline
Accuracy
(The number of elderly patients truly at risk of frailty assessed by the novel screening tool and G8 + the number of elderly patients truly without frailty risk) / Total number of elderly patients in the study
Time frame: Baseline
Specificity
(True elderly patients without frailty risk assessed by the novel screening tool and G8) / (True patients without frailty risk + elderly patients with positive results from novel screening tool but actually without frailty risk after G8 screening)
Time frame: Baseline
ORR
the sum percentage of participants with CR and PR assessed by RECIST v1.1 criteria every 8-12 weeks.
Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or the end of study, whichever came first, assessed up to 12 months.
PFS
Systemic Progression-Free Survival assessed by the investigators using RECIST V1.1.
Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months.
AE
Number and percentage of patents with treatment-related adverse events assessed by CTCAE v5.0.
Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sichuan Cancer Hospital and Research Institute